Genenta S.p.A.
(NASDAQ: GNTA)
|
8:30 PM UTC, 07/02/24 | |||
---|---|---|---|---|
Last: $3.09 | Change: +0.01 | %Change: +0.34% | Volume: 665 |
Open: | $ 3.30 | Volume: | 665 | |
---|---|---|---|---|
High: | $ 3.30 | Yield(%) | 0.00 | |
Low: | $ 3.09 | P/E Ratio (ttm): | n/a | |
Dividend ($): | n/a | Market Cap ($): | 56.29M | |
EPS ($) | n/a | Shares Out: | 18.22M |
% Price Change (last 4 weeks): | -3.63 |
---|---|
% Price Change (last 13 weeks): | -7.38 |
% Price Change (last 26 weeks): | -36.15 |
% Price Change (last 52 weeks): | -47.57 |
% Price Change (year to date): | -37.58 |
Return on Equity (%): | -45.12 |
---|---|
Return on Assets (%): | -41.71 |
Return on Invested Capital (%): | -30.27 |
Gross Profit Margin (%): | n/a |
---|---|
Net Profit Margin (%): | n/a |
Operating Profit Margin (%): | 0.00 |
50-day Moving Average: | $2.85 |
---|---|
200-day Moving Average: | $3.81 |
Avg. Daily Vol. (last 50 days): | 4,269 |
Avg. Daily Vol. (last 200 days): | 3,479 |
52-wk high: | $6.39 |
52-wk low: | $2.20 |
Bid: | $1.24 |
Ask: | $3.15 |
Genenta Science SpA is an early-stage company, which engages in the development of first-in-class cell and gene cancer therapies. Its lead product candidate, Temferon, was developed using its platform and carries an interferon-alpha payload. The company was founded by Pierluigi Paracchi, Luigi Naldini and Bernhard Gentner on July 24, 2014 and is headquartered in Milan, Italy.
|
Genenta S.p.A.
Via Olgettina No. 58 Milan MI 20132 Phone: 39.02.2643.4681 Fax: n/a http://www.genenta.com |
Earnings (1year) ($): | -0.69 |
---|---|
Annual Dividend ($): | 0.00 |
Current P/E Ratio (ttm): | n/a |
Book Value ($): | 1.24 |
Cash Flow ($): | -0.69 |
Price/Earnings (x): | n/a |
---|---|
Price/Sales (x): | n/a |
Price/Book (x): | 4.00 |
Price/Cash Flow (x): | n/a |
Quick Ratio (x): | 12.25 |
---|---|
Current Ratio (x): | 12.25 |
LT Debt/Equity (x): | 0.00 |
Total Debt/Equity (x): | 0.00 |